ACRS Q3 2023 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q3 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$9M-51.2% YoY

Gross Profit

$1M11.7% margin

Operating Income

-$32M-340.2% margin

Net Income

-$29M-315.2% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+396.6%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$218M

Total Liabilities

$62M

Stockholders' Equity

$156M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$19M	-51.2%
Gross Profit	$1M	$11M	-89.9%
Operating Income	-$32M	-$21M	-51.3%
Net Income	-$29M	-$20M	-46.7%

Revenue Segments

License and Service

$9M92%

Contract research

$705,0008%